yup Sarepta would be good. My money is on that, plus Receptos for a Shire buyout! They wanted to buy NPSP prior to the ABBVIE merger, so we'll see if that's back on the table. I'm still out of NPSP until I see this quarter results. (I was in big a couple months ago).
I already pointed this out in a recent post. Yes it's possible. Yes it would be a good fit given SHPG's drug portfolio and history of acquisitions to grow the pipeline. Happy now?
CEO has expressed interest in acquiring NPSP, NPS Pharmaceuticals. Interested in your feedback as to the possibility and validity of such a potential acquisition.
SHPG is on the prowl again... well they actually never stopped looking (just in the exact case ABBV pulled out). Will they be the Buyer or will they get Bought Out? One way or another we are due for some exciting times ahead.
@@@@@@Shire SHPG +5.14% PLC, the Dublin-based pharmaceutical company whose $54 billion merger with AbbVie Inc.ABBV +1.29% got called off earlier this month, says it’s looking at potential acquisitions of all sizes–particularly after it receives a “welcome addition to the bank account” via a $1.6 billion breakup fee from AbbVie on Monday. On a conference call with analysts Friday, Shire Chief Executive Flemming Ornskov said the company had continued to track potential large targets after the AbbVie deal was announced–even though it would have been difficult to actually pursue them–and thus ”did not miss a beat.” Even without the breakup fee, Mr. Ornskov pointed out that Shire completed a $4.5 billion acquisition in January of ViroPharma Inc. The deal, he said, speaks to the company’s ability to integrate and fund large deals. Analysts at Citigroup Inc.C +0.76% estimate that Shire could finance deals worth up to $13 billion. For now, executives said that Shire is actively looking at acquisition targets that complement with the company’s existing product portfolio of rare-disease drugs or would lead them into areas adjacent to their portfolio. Mr. Ornskov said Shire would be judicious about where it spends its money. Analysts say Shire still remains an attractive takeover target. The company’s business of selling drugs to treat rare diseases could make the company attractive to a number of large drug makers, they say.
Just got an order filled at $193. Have two more buy points at lower levels. Always put your orders in well in advance so you don't get caught up in the emotion.
SHPG was rumoured to be a buyout target repeatedly in recent years, and when ABBV finally came along I thought the story was finally over. Fortunately it is not. SHPG has been a very active acquirer and I expect them to continue to along that path. NPSP was a rumoured possible target before the ABBV news broke out, and I suspect SHPG will look to make a move soon now that they are free again and have that extra cash from the break fee in the bank.
SHPG has historically reported excellent results and steady growth over many years with only rare exceptions. In view of yet another great earnings report and strong guidance today, I decided to add a bit more at 195 . I plan to slowly rebuild a long position I recently exited at 260 after holding the stock for close to two decades. GLTA.
@@@@@Co increases guidance: Now expect to deliver Non GAAP earnings per ADS growth in the high thirty percent range in 2014 (previous guidance: low-to-mid thirty percent growth). Now expect product sales growth for the full year 2014 in the low twenty percent range (previous guidance: high teens growth).
Here's why: Allergan has been fighting off the vampire Valient's take over bid. Valient, if you didn't know, doesn't make anything. They just acquire companies, suck their pipeline, and move on to the next victim. John Paulsen who owns Allergan and Shire got caught up in this mess. He is down over a billion dollars on Shire since Abbvie fell through. The acquisition of Shire by Allergan would grow the balance sheet and deplete cash, significantly degrading Valient's ability to execute a hostile takeover. Since the Valient deal is being brokered by Bill Ackman, I further believe other activist shareholders like Icahn and Dan Loeb (both of whom have scored big taking the other side of Ackman's trades) would emerge to take the other side of Ackman's bet. Jim Chanos is already short Valient, because, again, they don't make anything (what Valient does is accounting manipulation on businesses they acquire....Ackman recently said that GAAP rules don't aplly to companies like Valient). More and more, I am convinced of this potential outcome and will be adding again on any pullbacks. I have nailed this trade thus far. Good luck.
I added more yesterday almost doubled my stake and once again wish I had added more. I wonder how Abbvie is feeling now. Quarterly growth of 33% on rev and EBITDA growth of 46% smash forecasts and guarantee the will hit the current annual forecasts which will likely be raised. As valuations increase future buyout premiums increase as well. Thank you panickers who dumped their shares!!! Your loss is my gain.
Haha... Not me... I am trying to rebuild a long position after cashing out at 260. So far only got a first small order filled at 165 and I want more!
No idea whether it will go up or down.... just pointing out that earnings will be out so there could be some significant movement up or down.
i picked up a small limit order in the last minute. I agree, we could get some dips to buy on. Some lucky person got $172 in extended hours yesterday. I am going to do some fishing tomorrow and see if I can pick up something with a limit order. It can drop $13 and I'm still in the money.
I wish I had bought more when this dropped and I am hoping for another dip. Now that we know the fair market value of this company, buying this was a no brainer. Now they are almost two billion dollars richer and STILL have buyout potential. This is going to be an interesting story in the months ahead.